Cargando…

Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing

Metastatic breast cancer (MBC) is frequently managed by platinum-based chemotherapy during the disease course. The real benefit of these treatments is uncertain at advanced stages of the disease and in non-triple-negative subtypes. Since homologous recombination deficiency (HRD) could inform about t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galland, Loïck, Ballot, Elise, Mananet, Hugo, Boidot, Romain, Lecuelle, Julie, Albuisson, Juliette, Arnould, Laurent, Desmoulins, Isabelle, Mayeur, Didier, Kaderbhai, Courèche, Ilie, Silvia, Hennequin, Audrey, Bergeron, Anthony, Derangère, Valentin, Ghiringhelli, François, Truntzer, Caroline, Ladoire, Sylvain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897409/ https://www.ncbi.nlm.nih.gov/pubmed/35246547 http://dx.doi.org/10.1038/s41523-022-00395-0

Ejemplares similares

Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers
por: Ballot, Elise, et al.
Publicado: (2022)

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer
por: Galland, Loïck, et al.
Publicado: (2023)

Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type
por: Dalens, Lorraine, et al.
Publicado: (2023)

Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer
por: Galland, Loïck, et al.
Publicado: (2021)

TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer
por: Lecuelle, Julie, et al.
Publicado: (2021)

Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results
por: Réda, Manon, et al.
Publicado: (2023)

Population Pharmacokinetics of Palbociclib in a Real-World Situation
por: Royer, Bernard, et al.
Publicado: (2021)

Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1
por: Galland, Loïck, et al.
Publicado: (2021)

MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer
por: Lecuelle, Julie, et al.
Publicado: (2022)

PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy
por: Tharin, Zoé, et al.
Publicado: (2023)

Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients
por: Marouille, Alexandre Le, et al.
Publicado: (2021)

Implementation and use of whole exome sequencing for metastatic solid cancer
por: Réda, Manon, et al.
Publicado: (2020)

Utility of exome sequencing in routine care for metastatic colorectal cancer
por: D'Agay, Melchior De Giraud, et al.
Publicado: (2021)

RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer
por: Ledys, Fanny, et al.
Publicado: (2018)

Is There a Role for Large Exome Sequencing in the Management of Metastatic Non-Small Cell Lung Cancer: A Brief Report of Real Life
por: Dalens, Lorraine, et al.
Publicado: (2022)

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma
por: Bertaut, Aurélie, et al.
Publicado: (2016)

Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study
por: Ladoire, Sylvain, et al.
Publicado: (2021)

Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study
por: Ladoire, Sylvain, et al.
Publicado: (2022)

Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer
por: Klopfenstein, Quentin, et al.
Publicado: (2021)

Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer
por: Kaderbhai, Coureche Guillaume, et al.
Publicado: (2016)

Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
por: Ilie, Silvia Mihaela, et al.
Publicado: (2023)

Using Exome Sequencing to Improve Prediction of FOLFIRINOX First Efficacy for Pancreatic Adenocarcinoma
por: Lecuelle, Julie, et al.
Publicado: (2021)

Tumor Infiltrating Lymphocytes Signature as a New Pan-Cancer Predictive Biomarker of Anti PD-1/PD-L1 Efficacy
por: Ballot, Elise, et al.
Publicado: (2020)

Custom multi-tumor next-generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three-year clinical use
por: Chevrier, Sandy, et al.
Publicado: (2022)

Using a convolutional neural network for classification of squamous and non-squamous non-small cell lung cancer based on diagnostic histopathology HES images
por: Le Page, Anne Laure, et al.
Publicado: (2021)

Liver X Receptor ligand cytotoxicity in colon cancer cells and not in normal colon epithelial cells depends on LXRβ subcellular localization
por: Courtaut, Flavie, et al.
Publicado: (2015)

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer
por: Kaderbhaï, Courèche, et al.
Publicado: (2019)

Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era
por: Kalfeist, Laura, et al.
Publicado: (2022)

Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness
por: Barnestein, Robby, et al.
Publicado: (2022)

Simultaneous isolation of CD45 tumor-infiltrating lymphocytes, tumor cells, and associated fibroblasts from murine breast tumor model by MACS
por: Kalfeist, Laura, et al.
Publicado: (2023)

Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series
por: Niogret, Julie, et al.
Publicado: (2022)

An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers
por: Chevrier, Sandy, et al.
Publicado: (2021)

FGF/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short report
por: Roussot, Nicolas, et al.
Publicado: (2023)

Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort
por: Tankere, Pierre, et al.
Publicado: (2022)

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
por: Derangère, Valentin, et al.
Publicado: (2016)

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
por: Thibaudin, Marion, et al.
Publicado: (2023)

Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives
por: Ledys, Fanny, et al.
Publicado: (2021)

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
por: Fumet, Jean-David, et al.
Publicado: (2018)

Correction: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
por: Fumet, Jean-David, et al.
Publicado: (2019)

GTN Enhances Antitumor Effects of Doxorubicin in TNBC by Targeting the Immunosuppressive Activity of PMN-MDSC
por: Mabrouk, Nesrine, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mogjnk3cm179hbin444nohtg22